Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Zai Lab LimitedNASDAQ: ZLAB

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $61.77M rose 22.0% year over year, ahead of the +3.2% change in trailing-twelve-month research & development. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.

Context

  • Research & development amounted to 48.0% of revenue in FY2025, down 10.8 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +3.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$61.77M-5.8% QoQ
Last fiscal yearDec 2025
$220.9M-5.8% YoY
LTMJun 2026
$236.92M+3.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.0%——
1 year-5.8%——
3-year CAGR-8.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
220.9M USD
Year-over-year change
-5.8%
4-year CAGR
-21.2%

Research & Development vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.2% is the 2nd highest of 3, against a peer median of -5.4%.
  • Research & development amounts to 52.7% of revenue for ZLAB, versus a peer median of 194.0%.
ZLAB Competitors
Research & Development for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥1.08B CNY+14.4%+13.4%194.0%
ZLABZai Lab LimitedLTM Jun 2026$236.92M USD+3.2%-8.3%52.7%
HCMHUTCHMED (China) LimitedLTM Jun 2025$190.1M USD-25.1%-15.0%31.6%
ANLAdlai Nortye Ltd.LTM Jun 2024$56.93M USD—-15.5%877.1%
Peer median (excluding ZLAB) —-5.4%-15.0%194.0%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.